Radioactive Preparation Carriers TRIZ Cases

DFOSq conjugates bind antibodies irreversibly, preventing zirconium-89 detachment and reducing toxic side effects.

Albumin-binding moieties in folate conjugates reduce renal retention and radionephrotoxicity while enhancing tumor accumulation.

Tetrapyrrole compound with hydrogelator and cleavage site self-assembles into aggregates upon enzymatic trigger.

A ligand-SIFA conjugate links a fibroblast activation protein binder to a silicon-fluoride acceptor moiety.

I-124 labeled antibodies enable positron emission tomography tracking of intravitreal agents in non-human primate models.

Acetate buffer stabilizes PCTA-anti-EGFR antibody complexes, eliminating extemporaneous preparation costs and radiation exposure risks.

Labeling HER2 aptamers with 18F or fluorescent dyes enables in vivo imaging, resolving the trade-off between target specificity and detection capability.

Modified fibronectin domains achieve high specificity for PD-L1 expression, resolving the trade-off between imaging capability and detection accuracy.

Cyclic peptide derivatives target GLP-1R receptors to resolve low contrast and poor quantification in pancreatic imaging.

Fluorescent trans-stilbene derivatives penetrate the blood-brain barrier to label myelin membranes.

An albumin-binding FAP inhibitor extends circulation time to increase tumor radioactivity accumulation while lowering single-dose biological dosimetry.

Proton irradiation creates 18F-labelled SF6 and CF4, addressing short isotope half-lives that limit PET ventilation diagnostics.

Combining alpha-emitting radiolabeled antibodies with immunocytokines overcomes limited efficacy of standalone radiolabeled antibodies.

Selective binding of 64Cu-DOTA-TATE to somatostatin receptors improves lesion detection rates while reducing radiation dose.

Albumin-binding PSMA ligands extend blood circulation half-life, increasing radiation dose deposited in tumors using commercially available 177Lu.

PET-CT imaging tracks radiolabeled ophthalmic agents to resolve uncertainty about agent persistence and systemic escape.

GPAID targets neuroblastoma through norepinephrine transport and DNA incorporation, reducing systemic toxicity while maintaining imaging capability.

Phospholipid ether analogs accumulate selectively in tumors, resolving FDG-PET false positives by targeting altered phospholipid metabolism.

Oral cholic acid clearance measurement replaces invasive liver biopsy to detect early dysfunction in chronic hepatitis C patients.

Radiolabeled phospholipid ether analogs selectively accumulate in malignant cells to enable simultaneous anatomical and functional detection via hybrid CT/PET scanning.

Mutated R-spondin polypeptides retain LGR binding while inhibiting Wnt signaling, enabling targeted delivery of cytotoxic agents to cancer stem cells.

Composite ligand-radionuclide agents resolve targeting precision versus delivery efficiency trade-offs in PET diagnostics.

Ergothioneine PET probes visualize biodistribution to overcome invasive analysis limitations, supporting neurodegenerative disease research.

Conjugating bismuth-213 to an anti-CD38 antibody targets CD38-expressing tumors, reducing relapse rates in multiple myeloma treatment.

Optimized peptide linkers reduce non-target tissue uptake while maintaining high tumor accumulation.

Novel radiolabeled stilbene compounds cross the blood-brain barrier to selectively bind amyloid aggregates.

Radiolabeled compounds targeting fibroblast activation protein utilize specific linker architectures to improve tumor uptake and imaging sensitivity.

DANBIRT radioligand binds LFA-1 on inflammatory leukocytes, enabling precise detection of atherosclerotic plaque vulnerability without invasive biopsy.

N-terminal modified cyclic peptides resist aqueous degradation while maintaining high specificity for fibroblast activation protein.

Gamma radiation emission from a radiotracer overcomes optical signal limitations, enabling high-sensitivity imaging of oxidative stress.

A silane-modified polyethylene glycol coated reaction vial enables rapid radiolabeling of prostate-specific membrane antigen ligands.

Room-temperature radiolabelling of dsIL2 with THP-mal resolves stability and binding trade-offs for PET imaging.

Replacing invasive biopsies, the radiolabeled tracer detects fibrotic tissue through specific receptor binding and external PET signal quantification.

Non-nucleophilic salts mediate NCA ring-opening polymerization to resolve polydispersity and molecular weight trade-offs in polypeptide synthesis.

Radiolabeled antibodies target IgA or IgM deposits in the kidney cortex for external detection via SPECT, PET, or MRI, replacing invasive renal biopsy.

Radiolabeled GRP78-binding agents overcome treatment resistance in castration-resistant prostate cancer by inducing ER stress and DNA damage response.

A metal chelating agent coordinates with a radiolabel to detect vascular calcification directly.

124I-labeled G250 antibodies bind carbonic anhydrase IX to enable specific bone metastasis detection via PET imaging.

A glutamic acid-urea compound modifies radioligand pharmacokinetics to enhance tumor uptake and retention time.

Dual-targeting ligands bind PSMA and GRPR to improve tumor uptake while reducing side effects from radionuclide therapy.

Cartilage-specific labeled compounds accumulate in tissue to resolve bone-cartilage boundaries, overcoming MRI resolution limits and invasive contrast toxicity.

Hyperpolarized 13C esters metabolize into unique signals to resolve tumor tissue differentiation limits.

Optimized benzamide scaffold with fluorine substitution improves melanoma uptake rates and image quality over conventional PET probes.

Technetium-99m labeled CSAs target infections and tumors, resolving detection accuracy and compound stability trade-offs.

Nitrogen ring chelators bind radioisotopes to octreotide derivatives, localizing radiation at tumor sites while sparing healthy tissue.

Radiolabeled stilbene derivatives cross the blood-brain barrier to enable in vivo myelin imaging and quantification.

Radical scavengers maintain high radioactivity concentrations and chemical stability in radiopharmaceuticals by preventing radiolysis-induced decomposition.